Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/08/2017 12/11/2017 12/12/2017 12/13/2017 12/14/2017 Date
106.09(c) 108(c) 109.04(c) 108.2(c) 108.24(c) Last
5 797 072 8 268 566 5 143 890 5 523 399 5 352 431 Volume
+3.27% +1.80% +0.96% -0.77% +0.04% Change
More quotes
Financials ($)
Sales 2017 12 967 M
EBIT 2017 7 286 M
Net income 2017 4 215 M
Debt 2017 4 463 M
Yield 2017 -
Sales 2018 14 829 M
EBIT 2018 8 584 M
Net income 2018 5 583 M
Finance 2018 575 M
Yield 2018 -
P/E ratio 2017 20,56
P/E ratio 2018 15,25
EV / Sales2017 6,91x
EV / Sales2018 5,71x
Capitalization 85 188 M
More Financials
Company
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases.Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in... 
Sector
Pharmaceuticals
Calendar
01/25Earnings Release
More about the company
Surperformance© ratings of Celgene Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CELGENE CORPORATION
12/14 CELGENE : DE/ Submission of Matters to a Vote of Security Holders (form 8-K/A)
12/14 CELGENE : Launches Celgene Cancer Care Links TM to Support Cancer Healthcare Cap..
12/14 CELGENE : Long-Term Efficacy Data from the Phase III GeparSepto Study in High Ri..
12/13 JUNO THERAPEUTICS : and Celgene Corporation Release Additional Data from TRANSCE..
12/13 JUNO THERAPEUTICS : and Celgene Corporation Release Additional Data from TRANSCE..
12/13 JUNO THERAPEUTICS : Highlights Key Translational Insights with JCAR017 in Patien..
12/13 Celgene, Gilead, and Regeneron are On the Mend
12/12 CELGENE CORPORATION : and bluebird bio Announce Updated Results from Ongoing Mul..
12/12 ACCELERON PHARMA : Announces Updated Results from Ongoing Phase 2 Trials of Lusp..
12/12 BEIGENE : falls on immune events for B cell cancer combo
More news
Sector news : Pharmaceuticals - NEC
12:05a Wall Street falls as investors fret about tax bill passage
12/14 TSX in broad retreat led by Cenovus, other energy stocks
12/14 Perrigo lines up bid for Merck's consumer health unit - sources
12/14 TEVA PHARMACEUTICAL INDUSTRIES : Pharm to lay off a quarter of workforce, suspen..
12/14DJTEVA PHARMACEUTICAL INDUSTRIES : to Cut 14,000 Jobs, Suspend Dividend -- Update
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on CELGENE CORPORATION 
CELGENE CORPORATION - 08/10
The resistance should give in
BUY
CELGENE CORPORATION - 04/28
Hesitation should subside in favor of volatility
BUY
More Strategies
News from SeekingAlpha
12/14 AGIOS PHARMACEUTICALS : Updates To Thesis And A Look Toward 2018
12/14 YOUR DAILY PHARMA SCOOP : Right Time To Buy Regeneron, Eli Lilly Gives Guidance,..
12/13 Why Tech Still Looks So Attractive
12/13 YOUR DAILY PHARMA SCOOP : Omeros Potential, Portola's Setback, Proteostasis Soar..
12/12 CUTTING EDGE GENE THERAPIES : Beta-Thalassemia Breakthroughs (Part I)
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 125 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-8.35%85 188
JOHNSON & JOHNSON21.53%383 877
NOVARTIS12.01%221 304
PFIZER10.04%218 400
ROCHE HOLDING LTD.3.40%210 833
MERCK AND COMPANY-6.96%155 214